SAN DIEGO - Kura Oncology, Inc. (NASDAQ:KURA) announced Tuesday it has completed the first U.S. commercial sale of KOMZIFTI (ziftomenib), its newly approved treatment for adults with relapsed or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback